PMS-METOPROLOL-L TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

METOPROLOL TARTRATE

から入手可能:

PHARMASCIENCE INC

ATCコード:

C07AB02

INN（国際名）:

METOPROLOL

投薬量:

50MG

医薬品形態:

TABLET

構図:

METOPROLOL TARTRATE 50MG

投与経路:

ORAL

パッケージ内のユニット:

100/500/1000

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0111923002; AHFS:

認証ステータス:

APPROVED

承認日:

1997-03-10

製品の特徴

PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................